Anti-endomysial antibody negative celiac disease: does additional serological testing help?

Area of Science:

• Gastroenterology
• Immunology
• Clinical Diagnostics

Background:

• Anti-endomysium antibodies (AEM) are used to screen for celiac disease (CD).
• AEM may not detect all untreated CD cases, potentially delaying diagnosis.
• Additional serological markers could improve CD detection rates.

Purpose of the Study:

• To evaluate if IgA anti-tissue transglutaminase (tTG) antibodies enhance the detection of celiac disease (CD) in patients with negative AEM results.
• To assess the diagnostic utility of other serological markers, including IgA and IgG anti-gliadin antibodies (AGA), in conjunction with AEM and IgA anti-tTG.

Main Methods:

• Prospective study of 53 biopsy-proven untreated CD patients and 65 controls.
• Measurement of serum total IgA, IgA anti-tTG, IgA AEM, IgA AGA, and IgG AGA antibodies.
• Analysis of AEM-negative CD patients for positivity in other tested antibody markers.

Main Results:

• 25% of untreated CD patients were negative for AEM.
• IgA anti-tTG and IgA AGA showed elevated levels in 3 AEM-negative CD patients.
• IgG AGA was elevated in 10 AEM-negative CD patients but also in 22% of controls.
• No IgA deficient CD patients were identified.

Conclusions:

• A significant proportion of untreated celiac disease (CD) cases are missed by anti-endomysium antibodies (AEM) alone.
• Testing for IgA anti-tissue transglutaminase (tTG) antibodies offers a modest improvement in detecting AEM-negative CD.
• Duodenal biopsy remains the gold standard for accurate celiac disease diagnosis.